HomeNewsScreenerMapsGroupsPortfolioInsiderFuturesForexCryptoCalendarPricing
Theme 		Help

New: Instantly spot drawdowns, dips, insider moves, and breakout themes across Maps and Screener.

Learn More
Market News Market Pulse Stocks News ETF News Crypto News

Phathom Pharmaceuticals

Contributing Author

Recent Articles by Phathom Pharmaceuticals

Jan-07
Phathom Pharmaceuticals Announces Pricing of $130 Million Public Offering of Common Stock and Pre-Funded Warrants PHAT GlobeNewswire
Jan-07
Phathom Pharmaceuticals Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants PHAT GlobeNewswire
Jan-07
Phathom Pharmaceuticals Announces Preliminary Fourth Quarter and Full Year 2025 Financial Results PHAT GlobeNewswire
Nov-04
Phathom Pharmaceuticals Announces First Patient Dosed in Phase 2 Study of VOQUEZNA (vonoprazan) in Eosinophilic Esophagitis (EoE) PHAT GlobeNewswire
Nov-03
Phathom Pharmaceuticals to Participate in Upcoming Investor Conferences PHAT GlobeNewswire
Oct-30
Phathom Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Business Update PHAT GlobeNewswire
Oct-25
Phathom Pharmaceuticals Announces Publication of Data from Phase 3 pHalcon-NERD-301 Study Showing VOQUEZNA (vonoprazan) Improved Nocturnal GERD Symptoms in Patients with Non-Erosive Reflux Disease PHAT GlobeNewswire
Oct-23
Phathom Pharmaceuticals to Highlight VOQUEZNA (vonoprazan) at the American College of Gastroenterology (ACG) 2025 Annual Scientific Meeting PHAT GlobeNewswire
Oct-20
Phathom Pharmaceuticals to Report Third Quarter 2025 Financial Results and Provide Business Update on Thursday, October 30, 2025 PHAT GlobeNewswire
Oct-06
Phathom Pharmaceuticals Appoints Sanjeev Narula as Chief Financial and Business Officer PHAT GlobeNewswire
Aug-25
Phathom Pharmaceuticals to Participate in Upcoming Investor Conferences PHAT GlobeNewswire
Aug-20
Phathom Pharmaceuticals Clarifies That There Is No Reduction in Lead Shareholder's Ownership Following Administrative Change to 13D Filing PHAT GlobeNewswire
Aug-07
Phathom Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Business Updates PHAT GlobeNewswire
Jul-28
Phathom Pharmaceuticals to Report Second Quarter 2025 Financial Results and Provide Business Update on Thursday, August 7, 2025 PHAT GlobeNewswire
Jun-23
Phathom Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) PHAT GlobeNewswire
Jun-23
Phathom Pharmaceuticals Appoints Anne Marie Cook as Chief Legal Officer and Corporate Secretary PHAT GlobeNewswire
Jun-16
Phathom Pharmaceuticals Announces FDA Correction to Orange Book Listing, Confirming 10 Years of Regulatory Exclusivity for VOQUEZNA (vonoprazan) Tablets Through May 3, 2032 PHAT GlobeNewswire
Jun-06
Phathom Pharmaceuticals Announces Positive FDA Decision to Recognize 10 Years of Regulatory Exclusivity for VOQUEZNA (vonoprazan) Tablets through May 3, 2032 PHAT GlobeNewswire
May-15
Phathom Pharmaceuticals to Participate in Upcoming Investor Conferences PHAT GlobeNewswire
May-01
Phathom Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) PHAT GlobeNewswire
Affiliate • Advertise • Careers • Contact • Blog • Help • Privacy • Follow us on X • Do Not Sell My Personal Information
Quotes delayed 15 minutes for NASDAQ, NYSE and AMEX.
Copyright © 2007-2026 Finviz.com. All Rights Reserved.